Axsome Acquires Exclusive Global Rights to Takeda's TAK-063
Axsome Therapeutics (AXSM) announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063, an oral, potent, and selective phosphodiesterase 10A inhibitor from Takeda (TAK). Axsome intends to develop the selective inhibitor for the treatment of schizophrenia and Tourette syndrome, and plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026. Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia. The selective PDE10A inhibitor has demonstrated a favorable safety and tolerability profile in clinical studies in over 360 individuals to date. Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect. Takeda received an upfront payment and is eligible to receive additional payments related to development, regulatory, and commercial milestones for the first two indications, as well as royalties related to potential global net sales.
